Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.

Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, Santilli MC, Regge MV, Lebersztein G, Levit C, Anfuso F, Castiglione T, Elizalde PV, Mercogliano MF, Schillaci R

Open source

DOI: 10.1136/jitc-2022-005325
Published: 2023 Mar
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2022-005325,
  title = {Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.},
  author = {Bruni S and Mauro FL and Proietti CJ and Cordo-Russo RI and Rivas MA and Inurrigarro G and Dupont A and Rocha D and Fernández EA and Deza EG and Lopez Della Vecchia D and Barchuk S and Figurelli S and Lasso D and Friedrich AD and Santilli MC and Regge MV and Lebersztein G and Levit C and Anfuso F and Castiglione T and Elizalde PV and Mercogliano MF and Schillaci R},
  year = {2023},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2022-005325},
  url = {https://doi.org/10.1136/jitc-2022-005325}
}

RIS

TY  - JOUR
TI  - Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
AU  - Bruni S
AU  - Mauro FL
AU  - Proietti CJ
AU  - Cordo-Russo RI
AU  - Rivas MA
AU  - Inurrigarro G
AU  - Dupont A
AU  - Rocha D
AU  - Fernández EA
AU  - Deza EG
AU  - Lopez Della Vecchia D
AU  - Barchuk S
AU  - Figurelli S
AU  - Lasso D
AU  - Friedrich AD
AU  - Santilli MC
AU  - Regge MV
AU  - Lebersztein G
AU  - Levit C
AU  - Anfuso F
AU  - Castiglione T
AU  - Elizalde PV
AU  - Mercogliano MF
AU  - Schillaci R
PY  - 2023
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2022-005325
UR  - https://doi.org/10.1136/jitc-2022-005325
ER  -

APA

S, B., FL, M., CJ, P., RI, C., MA, R., G, I., A, D., D, R., EA, F., EG, D., D, L. D. V., S, B., S, F., D, L., AD, F., MC, S., MV, R., G, L., C, L., F, A., T, C., PV, E., MF, M., & R, S. (2023). Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2022-005325

Source records

pubmed · retrieved 2026-09-26T17:08:29.895Z